Aclarion Appoints Daniel Keefe as Commercial Director to Drive Western U.S. Expansion of Nociscan

Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company using biomarkers and artificial intelligence to identify the source of chronic low back pain, announced the appointment of Daniel Keefe as Commercial Director for the Western United States. The move signals the company's commitment to scaling adoption of its Nociscan platform amid rising demand, supported by triple-digit growth in utilization.

Keefe brings over 20 years of medical device and healthcare technology sales experience, including leadership roles at Centinel Spine, Brainlab, Zimmer Biomet, and Intuitive Surgical. Most recently, as Regional Sales Manager at Centinel Spine, he consistently exceeded performance targets and delivered significant year-over-year growth across Northern California. His expertise in building strategic relationships with surgeons and hospital systems will be instrumental as Aclarion deepens its presence in a key strategic region.

"Dan brings a proven track record of driving commercial growth and expanding adoption of innovative surgical technologies," said Brent Ness, Chief Executive Officer of Aclarion. "His deep experience working with spine surgeons and hospital systems, combined with his ability to build and scale high-performing territories, will be instrumental as we continue to grow our presence in the Western U.S. and support broader clinical use of Nociscan."

Nociscan is the first evidence-supported, cloud-based platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. It quantifies chemical biomarkers associated with disc pain and, when used with other diagnostic tools, provides critical insights into the location of pain. According to Aclarion, Nociscan demonstrates a 97% surgical success rate when all Nociscan-positive discs are treated. With an estimated 266 million people worldwide suffering from chronic low back pain, the technology addresses one of the most pervasive health challenges.

Keefe expressed enthusiasm about joining Aclarion at a time of growing clinical traction. "The ability to provide physicians with objective insight into the source of pain represents a significant advancement in how chronic low back pain is evaluated," he said. "I look forward to working with physicians and spine centers across the Western U.S. to expand access to Nociscan and support its continued integration into clinical practice."

Aclarion has established a growing footprint across the Western U.S., with engagement spanning academic institutions and high-volume private practice spine centers. The company's expansion of its commercial team reflects increasing demand for Nociscan, supported by strong volume growth. For more information on Nociscan, visit the Aclarion newsroom.